PET imaging in clinical drug abuse research

S. John Gatley, Nora D. Volkow, Gene Jack Wang, Joanna S. Fowler, Jean Logan, Yu Shin Ding, Madina Gerasimov

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


Over the last two decades, SPECT (single photon emission computed tomography) and especially PET (positron emission tomography) have proven increasingly effective imaging modalities in the study of human psychopharmacology. Abusing populations can be studied at multiple times after abstinence begins, to give information about neurochemical and physiological adaptations of the brain during recovery from addiction. Individual human subjects can be studied using multiple positron labeled radiotracers, so as to probe more than one facet of brain function. PET and SPECT have been used to help our understanding of many aspects of the pharmacokinetics and pharmacodynamics of abused drugs, and have made valuable contributions in terms of drug mechanisms, drug interactions (e.g. cocaine and alcohol) and drug toxicities. They have also been employed to study the acute effects of drugs on populations of active drug abusers and of normal controls, and to evaluate the neurochemical consequences of candidate therapies for drug abuse. A particularly productive strategy has been the use of PET in conjunction with neuropsychological testing of subjects, to allow correlation of imaging data with uniquely human aspects of the effects of drugs, such as euphoria and craving.

Original languageEnglish
Pages (from-to)3203-3219
Number of pages17
JournalCurrent Pharmaceutical Design
Issue number25
StatePublished - 2005
Externally publishedYes


Dive into the research topics of 'PET imaging in clinical drug abuse research'. Together they form a unique fingerprint.

Cite this